|
MBTD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.24769999998442E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.94018999999379E-05 |
| Normal-vs-Stage2 |
9.86010000000315E-05 |
| Normal-vs-Stage3 |
1.65550000041925E-07 |
| Normal-vs-Stage4 |
1.5812000000448E-06 |
| Stage1-vs-Stage2 |
4.575400E-01 |
| Stage1-vs-Stage3 |
7.084200E-02 |
| Stage1-vs-Stage4 |
7.973900E-02 |
| Stage2-vs-Stage3 |
5.707000E-01 |
| Stage2-vs-Stage4 |
4.078200E-01 |
| Stage3-vs-Stage4 |
7.112600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.04799999958816E-07 |
| Normal-vs-AfricanAmerican |
1.558120E-02 |
| Normal-vs-Asian |
8.420900E-04 |
| Caucasian-vs-AfricanAmerican |
4.911400E-01 |
| Caucasian-vs-Asian |
4.195400E-01 |
| AfricanAmerican-vs-Asian |
9.272800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.26270000003304E-06 |
| Normal-vs-Female |
3.29669999965532E-07 |
| Male-vs-Female |
8.929400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.50499999999454E-05 |
| Normal-vs-Age(41-60Yrs) |
3.19569999995828E-06 |
| Normal-vs-Age(61-80Yrs) |
2.19150000035917E-07 |
| Normal-vs-Age(81-100Yrs) |
9.023000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.025800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.609900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.428000E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.981230E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.506150E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.234000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.360020E-03 |
| Classical-VS-Follicular |
1.054000E-01 |
| Classical-VS-Other |
8.420200E-01 |
| Classical-VS-Normal |
1.88701999999097E-05 |
| Tall-VS-Follicular |
1.035210E-01 |
| Tall-VS-Other |
9.378500E-02 |
| Tall-VS-Normal |
8.5801999949453E-08 |
| Follicular-VS-Other |
5.147400E-01 |
| Follicular-VS-Normal |
1.91699999999573E-05 |
| Other-VS-Normal |
1.684650E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.57270000045973E-07 |
| Normal-vs-N1 |
4.47359999999897E-05 |
| N0-vs-N1 |
8.344800E-01 |
|
|
